We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
For the quarter ended September 2023, Johnson & Johnson (JNJ - Free Report) reported revenue of $21.35 billion, down 10.3% over the same period last year. EPS came in at $2.66, compared to $2.55 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $21 billion, representing a surprise of +1.67%. The company delivered an EPS surprise of +5.56%, with the consensus EPS estimate being $2.52.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Johnson & Johnson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Organic Sales Growth (Operational growth): 6.4% compared to the 5.8% average estimate based on three analysts.
Sales- Innovative Medicine- Neuroscience- Spravato- WW: $183 million compared to the $194.42 million average estimate based on five analysts.
Sales- Innovative Medicine- Oncology- Carvykti- WW: $152 million versus the five-analyst average estimate of $148.03 million.
Sales- MedTech- Orthopaedics - Hips - US: $239 million compared to the $247.22 million average estimate based on four analysts.
Sales- MedTech- Orthopaedics - Hips - International: $136 million versus the four-analyst average estimate of $123.72 million.
Sales- MedTech - Total: $7.46 billion versus $7.59 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10% change.
Sales- Innovative Medicine - Total: $13.89 billion compared to the $13.37 billion average estimate based on six analysts. The reported number represents a change of +5.1% year over year.
Sales- MedTech- Orthopaedics - Trauma: $742 million compared to the $751.11 million average estimate based on five analysts.
Sales- MedTech- Orthopaedics - Spine, Sports & Other: $710 million versus the five-analyst average estimate of $739.03 million.
Sales- MedTech- Surgery - Advanced: $1.16 billion versus $1.21 billion estimated by five analysts on average.
Sales- MedTech- Surgery - Total: $2.48 billion versus $2.54 billion estimated by five analysts on average.
Sales- Innovative Medicine- Oncology - Imbruvica: $808 million versus the five-analyst average estimate of $771.27 million. The reported number represents a year-over-year change of -11.3%.
Shares of Johnson & Johnson have returned -3% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended September 2023, Johnson & Johnson (JNJ - Free Report) reported revenue of $21.35 billion, down 10.3% over the same period last year. EPS came in at $2.66, compared to $2.55 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $21 billion, representing a surprise of +1.67%. The company delivered an EPS surprise of +5.56%, with the consensus EPS estimate being $2.52.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Johnson & Johnson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Sales Growth (Operational growth): 6.4% compared to the 5.8% average estimate based on three analysts.
- Sales- Innovative Medicine- Neuroscience- Spravato- WW: $183 million compared to the $194.42 million average estimate based on five analysts.
- Sales- Innovative Medicine- Oncology- Carvykti- WW: $152 million versus the five-analyst average estimate of $148.03 million.
- Sales- MedTech- Orthopaedics - Hips - US: $239 million compared to the $247.22 million average estimate based on four analysts.
- Sales- MedTech- Orthopaedics - Hips - International: $136 million versus the four-analyst average estimate of $123.72 million.
- Sales- MedTech - Total: $7.46 billion versus $7.59 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10% change.
- Sales- Innovative Medicine - Total: $13.89 billion compared to the $13.37 billion average estimate based on six analysts. The reported number represents a change of +5.1% year over year.
- Sales- MedTech- Orthopaedics - Trauma: $742 million compared to the $751.11 million average estimate based on five analysts.
- Sales- MedTech- Orthopaedics - Spine, Sports & Other: $710 million versus the five-analyst average estimate of $739.03 million.
- Sales- MedTech- Surgery - Advanced: $1.16 billion versus $1.21 billion estimated by five analysts on average.
- Sales- MedTech- Surgery - Total: $2.48 billion versus $2.54 billion estimated by five analysts on average.
- Sales- Innovative Medicine- Oncology - Imbruvica: $808 million versus the five-analyst average estimate of $771.27 million. The reported number represents a year-over-year change of -11.3%.
View all Key Company Metrics for Johnson & Johnson here>>>Shares of Johnson & Johnson have returned -3% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.